TrialDiabetes, obesity & metabolism2021

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Muthiah Vaduganathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.